Diphenhydramine
- Generic Name
- Diphenhydramine
- Brand Names
- Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 58-73-1
- Unique Ingredient Identifier
- 8GTS82S83M
- Background
Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both ...
- Indication
Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insom...
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes
- Associated Therapies
- Airway secretion clearance therapy, Expectorant
FDA approves neffy, new nasal spray to treat severe allergic reactions
The FDA approved neffy, a nasal spray for treating anaphylaxis, offering advantages like no needle and stable shelf life. While effective, some, like Uma Krishnamoorthy and Jake Tong, remain cautious due to neffy's recent introduction and potential side effects. Krishnamoorthy and Dr. James Wolfe anticipate neffy becoming a viable alternative to EpiPens as it gains more acceptance.
Pafolacianine Shows No Serious Adverse Effects in Lung Cancer Surgery
No serious adverse effects observed with pafolacianine use in lung cancer surgery patients. Common side effects include flushing, itching, and nausea, treated with diphenhydramine and anti-nausea meds. Safety confirmed in ELUCIDATE trial.
Why the FDA wants to pull this common cold medicine ingredient from shelves
The FDA proposes removing phenylephrine from cold medicines like NyQuil, Benadryl, and Sudafed due to its ineffectiveness in pill or syrup form, despite being effective in nasal sprays. Dr. Randy Hatton, a University of Florida professor, has been advocating for this change for two decades, noting that phenylephrine replaced pseudoephedrine when the latter was restricted for methamphetamine production.
FDA to Finally Ban Controversial Ingredient in Popular Decongestants
The FDA proposes removing oral phenylephrine from decongestants due to its ineffectiveness, impacting $1.76 billion market. Popular products like Advil Sinus, Sudafed PE, Vicks DayQuil, and Tylenol Cold & Flu may be affected. Phenylephrine, once deemed effective in 1976, was criticized for lack of efficacy in 2005 and 2007, leading to ongoing debate. The FDA's decision follows recent trials confirming its ineffectiveness at any dose.
FDA Plans to Ban Ineffective Cold Medicine Ingredient—How It Will Affect You
FDA proposes to ban oral phenylephrine from OTC drugs due to ineffectiveness in treating nasal congestion, despite its common use in cold medications. Public comment period open until May 7, 2025, with no safety concerns cited. Proposal does not affect nasal spray form. Alternatives include nasal sprays, oral pseudoephedrine, and antihistamine nasal sprays.
FDA proposes banning oral phenylephrine in decongestants
FDA seeks to ban oral phenylephrine in OTC nasal decongestants due to ineffectiveness; no safety concerns; found in NyQuil, Benadryl, Sudafed, Mucinex; public comment period open.
Yellowjackets and Bees Swarm in NC in Helene's Aftermath
Hurricane Helene's flooding in NC uprooted yellow jackets and bees' nests, causing a surge in stinging incidents. NC DHHS is procuring Benadryl and epinephrine, while Direct Relief has delivered over 2,000 EpiPens. Pharmacists offer emergency refills, and the state plans to allow over-the-counter epinephrine sales. Severe allergic reactions to stings can lead to anaphylaxis, requiring immediate epinephrine administration. Avoiding perfumes and wearing light-colored clothing can reduce stinging risks.
11-year-old Georgia girl survives cancer and aims to help others
After frequent bruises led to a leukemia diagnosis for Ally, her family faced a challenging treatment journey. Precision medicine revealed Ally and her father share Lynch syndrome, increasing cancer risk. Now cancer-free, Ally uses her experience to raise awareness and funds for childhood cancer.
Hill Holliday launches new healthcare practice dubbed Quest, aiming to 'infuse new energy
Hill Holliday launches new healthcare practice, Hill Holiday Quest, led by former Pfizer executive Christy Lopé. The practice aims to tackle healthcare challenges from a client perspective, leveraging Hill Holliday’s DTC experience and Lopé’s expertise in consumer health and wellness brands. Quest seeks to bring fresh energy to the healthcare market by drawing on Hill Holliday’s broader network of non-health verticals.
Wanbury announces new API product portfolio and launch plans
Wanbury launches new API portfolio for FY24-25, including high-demand products like Metformin HCl, Sertraline HCl, and Diphenhydramine HCl. The company plans regulatory filings for USDMF and CEP, aligning with USP, Ph. Eur., and BP standards to meet global pharmaceutical needs.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath